{"denoms":[{"counts":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"26"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"12"},{"groupId":"BG009","value":"9"},{"groupId":"BG010","value":"28"},{"groupId":"BG011","value":"208"}],"units":"Participants"}],"groups":[{"description":"Participants with NSCLC were treated with vemurafenib monotherapy.","id":"BG000","title":"Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib"},{"description":"Participants with ovarian cancer were treated with vemurafenib monotherapy.","id":"BG001","title":"Cohort 2: Ovarian Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib monotherapy.","id":"BG002","title":"Cohort 3a: Colorectal Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.","id":"BG003","title":"Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab"},{"description":"Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.","id":"BG004","title":"Cohort 4: Cholangiocarcinoma - Vemurafenib"},{"description":"Participants with multiple myeloma were treated with vemurafenib monotherapy.","id":"BG005","title":"Cohort 6: Multiple Myeloma - Vemurafenib"},{"description":"Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.","id":"BG006","title":"Cohort 7a: ECD/LCH - Vemurafenib"},{"description":"Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.","id":"BG007","title":"Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib"},{"description":"Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.","id":"BG008","title":"Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib"},{"description":"Participants with early stage astrocytoma were treated with vemurafenib monotherapy.","id":"BG009","title":"Cohort 7d: Early Stage Astrocytoma - Vemurafenib"},{"description":"Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.","id":"BG010","title":"Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib"},{"description":"Total of all reporting groups","id":"BG011","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.2","value":"65.4"},{"groupId":"BG001","spread":"5.3","value":"45.8"},{"groupId":"BG002","spread":"5.4","value":"57.3"},{"groupId":"BG003","spread":"8.8","value":"64.3"},{"groupId":"BG004","spread":"9.7","value":"53.2"},{"groupId":"BG005","spread":"4.3","value":"62.1"},{"groupId":"BG006","spread":"13.3","value":"60.8"},{"groupId":"BG007","spread":"9.2","value":"66.8"},{"groupId":"BG008","spread":"12.2","value":"41.6"},{"groupId":"BG009","spread":"20.7","value":"34.3"},{"groupId":"BG010","spread":"17.5","value":"53.7"},{"groupId":"BG011","spread":"14.5","value":"59.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"8"},{"groupId":"BG009","value":"9"},{"groupId":"BG010","value":"15"},{"groupId":"BG011","value":"111"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"13"},{"groupId":"BG011","value":"97"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat (ITT) population included all participants enrolled in the study irrespective of whether they had received study medication or not."}